Phaseline

Targets › VZV

VZV: drug programs, companies and trials

6 programs from 5 companies in 12 trials: 4 Phase 2, 4 Phase 1, 2 Phase 4, 2 Phase 3; Infectious disease, Vaccines, Immunology; next expected readout Dec 2026.

Open in Phaseline: the race on VZV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peking University Third HospitalBrivudine
Nucleoside analog antiviral inhibiting herpes zoster virus DNA polymerase
VZVPhase 4Herpes ZosterDec 2026
University of Sao Paulo General HospitalAcyclovir
Human herpesvirus 1 DNA polymerase inhibitor
HSV1, HSV2, VZVPhase 4Autoimmune Rheumatic DiseasesApr 2027
MAXVAX Biotechnology Limited Liability CompanyVaricella Zoster Virus Envelope Glycoprotein E
Envelope glycoprotein E vaccine antigen
VZGP5, VZVPhase 3Herpes ZosterNov 2027
Guangzhou Patronus BiotechLYB004
Recombinant varicella zoster virus glycoprotein E (VZV-gE) vaccine adjuvanted with A01B or
VZVPhase 2Herpes Zoster (HZ); Herpes ZosterDec 2026
Green CrossMG1111 (BARICELA)
Varicella-zoster virus vaccine
VZVPhase 2VaricellaJun 2027
MAXVAX Biotechnology Limited Liability CompanyRecombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105
Recombinant varicella zoster virus glycoprotein E vaccine with low dose MA105 adjuvant
VZV, VZVAPhase 2Herpes Zoster–

Conditions

Herpes Zoster (8) Herpes Zoster (HZ) (2) Varicella (1) Autoimmune Rheumatic Diseases (1)

Modalities

protein or peptide (2), small molecule (2), other (1), mixed (1)

Companies

MAXVAX Biotechnology Limited Liability Company (2) Green Cross (1) Guangzhou Patronus Biotech (1) University of Sao Paulo General Hospital (1) Peking University Third Hospital (1)

Related targets

HSV1 (1) HSV2 (1) VZGP5 (1) VZVA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.